Denali Therapeutics Overview

  • Founded
  • 2015
Founded
  • Status
  • Public
  • Employees
  • 334
Employees
  • Stock Symbol
  • DNLI
Stock Symbol
  • Investments
  • 3
  • Share Price
  • $47.80
  • (As of Friday Closing)

Denali Therapeutics General Information

Description

Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Primary Office
  • 161 Oyster Point Boulevard
  • South San Francisco, CA 94080
  • United States
+1 (650) 000-0000

Denali Therapeutics Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Denali Therapeutics Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$47.80 $46.17 $39.09 - $93.94 $5.81B 122M 519K $0.42

Denali Therapeutics Financials Summary

In Thousands,
USD
TTM 30-Jun-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 8,160,961 9,153,087 1,263,389 1,586,856
Revenue 357,070 335,659 26,678 129,160
EBITDA 59,514 71,249 (205,193) (38,957)
Net Income 55,925 71,136 (197,614) (36,240)
Total Assets 1,509,815 1,604,280 553,231 661,984
Total Debt 66,451 68,865 72,530 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Denali Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Denali Therapeutics‘s full profile, request access.

Request a free trial

Denali Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Denali Therapeutics‘s full profile, request access.

Request a free trial

Denali Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat
Biotechnology
South San Francisco, CA
334 As of 2021
00.000
000000000 00.000

00000000

nim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequ
0000000000000
South San Francisco, CA
00 As of 0000
00000
000000000 00000

0000000

et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut
0000 000000000
Berwyn, PA
0 As of 0000
000.00
00000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Denali Therapeutics Competitors (40)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Cortexyme Formerly VC-backed South San Francisco, CA 00 00000 000000000 00000
0000000 000 Formerly VC-backed Berwyn, PA 0 000.00 00000000 000.00
000000000 Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
000000 00000000000 Corporation Toronto, Canada 0 000.00 00000000 000.00
000000 00000000000 Corporation Cambridge, MA 000 00000 000000 - 000 00000
You’re viewing 5 of 40 competitors. Get the full list »

Denali Therapeutics Executive Team (10)

Name Title Board Seat Contact Info
Ryan Watts Ph.D President, Chief Executive Officer & Co-Founder
Steve Krognes Chief Financial Officer
Alexander Schuth Co-Founder & Chief Operating Officer
Dana Andersen Ph.D Chief Technical and Manufacturing Officer
Cindy Dunkle Chief People Officer
You’re viewing 5 of 10 executive team members. Get the full list »

Denali Therapeutics Board Members (12)

Name Representing Role Since
David Schenkein MD ARCH Venture Partners Board Member 000 0000
Douglas Cole MD Flagship Pioneering Board Member 000 0000
Jay Flatley Self Board Member 000 0000
Jennifer Cook Denali Therapeutics Board Member 000 0000
Marc Tessier-Lavigne Ph.D Denali Therapeutics Board Member 000 0000
You’re viewing 5 of 12 board members. Get the full list »

Denali Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Denali Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Denali Therapeutics‘s full profile, request access.

Request a free trial

Denali Therapeutics Investments & Acquisitions (3)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0-0000 00000 30-May-2018 000000000000000000 00000 Biotechnology 0000 00000 00.0
00000 000000000000 25-Aug-2016 000000000000000000 Biotechnology 000000 00 00
F-star Gamma 05-Jun-2016 Secondary Transaction - Private 000 Biotechnology 0000 00000 00.0
To view Denali Therapeutics’s complete investments and acquisitions history, request access »